检索结果 - Enrico Cortesi
- Showing 1 - 20 results of 37
- Go to Next Page
-
1
-
2
-
3
-
4
-
5
PD-L1 and epithelial-mesenchymal transition in circulating tumor cells from non-small cell lung cancer patients: A molecular shield to evade immune system<b>?</b> 由 Cristina Raimondi, Guido Carpino, Chiara Nicolazzo, Angela Gradilone, Walter Gianni, Alain Gelibter, Eugenio Gaudio, Enrico Cortesi, Paola Gazzaniga
出版 2017Artigo -
6
Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal Cancer 由 Cristina Raimondi, Chiara Nicolazzo, Francesca Belardinilli, Flavia Loreni, Angela Gradilone, Yasaman Mahdavian, Alain Gelibter, Giuseppe Giannini, Enrico Cortesi, Paola Gazzaniga
出版 2019Artigo -
7
-
8
Chemotherapy of advanced non-small-cell lung cancer: A comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.) 由 Lucio Crinò, M. Clerici, F. Figoli, Paolo Carlini, Guido Ceci, Enrico Cortesi, A Carpi, Alessandra Santini, Francesco Di Costanzo, C. Boni
出版 1995Artigo -
9
Circulating Tumor Cells Identify Patients with Super-High-Risk Non-Muscle-Invasive Bladder Cancer: Updated Outcome Analysis of a Prospective Single-Center Trial 由 Chiara Nicolazzo, Gian Maria Busetto, Angela Gradilone, Isabella Sperduti, Francesco Del Giudice, Flavia Loreni, Enrico Cortesi, Ettore De Berardinis, Paola Gazzaniga, Cristina Raimondi
出版 2019Artigo -
10
Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab 由 Chiara Nicolazzo, Cristina Raimondi, M. Mancini, S Caponnetto, Angela Gradilone, Orietta Gandini, Maria Mastromartino, Gabriella Del Bene, Alessandra Anna Prete, Flavia Longo, Enrico Cortesi, Paola Gazzaniga
出版 2016Artigo -
11
nmCRPC, a look in the continuous care of prostate cancer patients: state of art and future perspectives 由 Alfredo Berruti, Sergio Bracarda, Orazio Caffo, Enrico Cortesi, Rolando Maria D’Angelillo, Marzia Del Re, Gaetano Facchini, Giovanni Pappagallo, Giuseppe Procopio, Roberto Sabbatini, Daniele Santini
出版 2023Revisão -
12
Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma 由 Matteo Santoni, Ugo De Giorgi, Roberto Iacovelli, Alessandro Conti, Luciano Burattini, Lorena Rossi, Salvatore Luca Burgio, Rossana Berardi, Giovanni Muzzonigro, Enrico Cortesi, D. Amadori, Stefano Cascinu
出版 2013Artigo -
13
Immune effects of CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: Relief from immunosuppression is associated with clinical response 由 Fabio Scirocchi, Simone Scagnoli, Andrea Botticelli, Alessandra Di Filippo, Chiara Napoletano, Ilaria Grazia Zizzari, Lidia Strigari, Federica Tomao, Enrico Cortesi, Aurelia Rughetti, Paolo Marchetti, Marianna Nuti
出版 2022Artigo -
14
Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization 由 Angela Gradilone, Giuseppe Naso, Cristina Raimondi, Enrico Cortesi, Orietta Gandini, Bruno Vincenzi, Rosa Saltarelli, E. Chiapparino, Franco Spremberg, Massimo Cristofanilli, Luigi Frati, Anna Maria Aglianò, Paola Gazzaniga
出版 2010Artigo -
15
Epidermal Growth Factor Receptor Gene Copy Number and Clinical Outcome of Metastatic Colorectal Cancer Treated With Panitumumab 由 Andrea Sartore‐Bianchi, Mauro Moroni, Silvio Veronese, Carlo Carnaghi, Emilio Bajetta, Gabriele Luppi, Alberto Sobrero, Carlo Barone, Stefano Cascinu, Giuseppe Colucci, Enrico Cortesi, Michele Nichelatti, Marcello Gambacorta, Salvatore Siena
出版 2007Artigo -
16
Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised ‘GISCAD’ trial 由 Roberto Labianca, Alberto F. Sobrero, L. Isa, Enrico Cortesi, Sandro Barni, Dario Nicolella, Massimo Aglietta, Sara Lonardi, Domenico Corsi, D. Turci, Giordano Beretta, Giuseppe Fornarini, E. Dapretto, Irene Floriani, Alberto Zaniboni
出版 2010Artigo -
17
Adjuvant Chemotherapy in Completely Resected Gastric Cancer: A Randomized Phase III Trial Conducted by GOIRC 由 Francesco Di Costanzo, Silvia Gasperoni, L. Manzione, Giancarlo Bisagni, Roberto Labianca, Stefano Bravi, Enrico Cortesi, Paolo Carlini, R. Bracci, Federica Tomao, Luca Messerini, Annarosa Arcangeli, Valter Torri, D. Bilancia, Irene Floriani, Maurizio Tonato
出版 2008Artigo -
18
The role of opioids in cancer response to immunotherapy 由 Andrea Botticelli, Alessio Cirillo, Giulia Pomati, Bruna Cerbelli, Simone Scagnoli, Michela Roberto, Alain Gelibter, Giulia Mammone, Maria Letizia Calandrella, Edoardo Cerbelli, Francesca Romana Di Pietro, Federica De Galitiis, Gaetano Lanzetta, Enrico Cortesi, Silvia Mezi, Paolo Marchetti
出版 2021Artigo -
19
Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First... 由 Alfredo Falcone, Sergio Ricci, I. Brunetti, E. Pfanner, Giacomo Allegrini, C. Barbara, Lucio Crinò, Giovanni Benedetti, W. Evangelista, Laura Fanchini, Enrico Cortesi, V. Picone, S. Vitello, Silvana Chiara, Cristina Granetto, Gianfranco Porcile, Luisa Fioretto, Cinzia Orlandini, M. Andreuccetti, Gianluca Masi
出版 2007Artigo -
20
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer 由 Fotios Loupakis, Chiara Cremolini, Gianluca Masi, Sara Lonardi, Vittorina Zagonel, Lisa Salvatore, Enrico Cortesi, Gianluca Tomasello, M. Ronzoni, Rosella Spadi, Alberto Zaniboni, Giuseppe Tonini, Angela Buonadonna, D. Amoroso, Silvana Chiara, Chiara Carlomagno, C. Boni, Giacomo Allegrini, Luca Boni, Alfredo Falcone
出版 2014Artigo
相关主题
Internal medicine
Medicine
Oncology
Cancer
Chemotherapy
Colorectal cancer
Gastroenterology
Surgery
Cancer research
Immunotherapy
Metastasis
Biology
Adverse effect
Breast cancer
Lung cancer
Oxaliplatin
Circulating tumor cell
Renal cell carcinoma
Clinical trial
Confidence interval
Fluorouracil
Immunology
Irinotecan
Metastatic breast cancer
Nivolumab
Progression-free survival
Bevacizumab
FOLFIRI
Phases of clinical research
Proportional hazards model